Blueprint Medicines Corp

NASDAQ:BPMC   3:59:43 PM EDT
103.14
-1.53 (-1.46%)
Products, Regulatory

Blueprint Medicines Announces European Commission Approval Of Ayvakyt® (Avapritinib) For The Treatment Of Adults With Unresectable Or Metastatic Pdgfra D842v Mutant Gastrointestinal Stromal Tumo

Published: 09/25/2020 18:27 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Announces European Commission Approval of Ayvakyt® (avapritinib) for the Treatment of Adults With Unresectable Or Metastatic Pdgfra D842v Mutant Gastrointestinal Stromal Tumors.
Blueprint Medicines Corp - 95% Orr and 22.1 Month Median Dor in Patients With Unresectable Or Metastatic Pdgfra D842v Mutant Gist in Navigator Trial1.
Blueprint Medicines Corp - Ayvakyt Was Generally Well-tolerated in Patients With Pdgfra D842v Mutant Gist With Or Without Prior Therapy.
Blueprint Medicines Corp - in Europe, Plans to Initiate Its First Commercial Launch of Ayvakyt in Germany Following Ec Approval.
Blueprint Medicines Corp - Timing of Ayvakyt Availability Will Vary for Other Countries in Europe Based on Local Reimbursement and Access Pathways.
Blueprint Medicines Corp - Plans to Conduct an Observational, Long-term Study in Patients With Pdgfra D842v Mutant Gist Treated With Ayvakyt.
Blueprint Medicines Corp - Median Progression-free Survival (pfs) Was 24 Months, and Median Overall Survival (os) Was Not Reached for Ayvakvt.